Soleno Therapeutics reports FY profit for 2025

Soleno Therapeutics

25/02/2026 21:10

Overview

Biopharmaceutical firm's Q4 revenue from VYKAT XR reached $91.7 mln

Company achieved profitability with $20.9 mln net income for 2025

Company invested $100 mln in accelerated share repurchase program

Outlook

Soleno plans to pursue EU regulatory approval for VYKAT XR

Company to evaluate VYKAT XR for additional rare diseases

Result Drivers

VYKAT XR LAUNCH - Successful U.S. launch of VYKAT XR drove revenue to $91.7 mln in Q4

PATIENT START FORMS - Over 1,250 patient start forms received since approval, including 207 in Q4

UNIQUE PRESCRIBERS - 630 unique prescribers, with 136 new in Q4, contributed to sales growth

Company press release: ID:nGNXJTvy5

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
$0.80
Q4 Net Income
$43.36 mln
Q4 Basic EPS
$0.82
Q4 Operating Expenses
$52.15 mln
Q4 Operating Income
$39.58 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Soleno Therapeutics Inc is $114.00, about 191.1% above its February 24 closing price of $39.16

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 28 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)